Martin S. Tallman was named director of faculty mentorship and career development at Lurie Cancer Center, effective June 1. Tallman will focus on the management and development of treatments for patients with both acute and chronic leukemias.
Positive high-level results from an interim analysis of the AMPLIFY phase III trial showed a fixed duration of Calquence (acalabrutinib) in combination with venetoclax, with or without obinutuzumab, demonstrated a statistically significant and clinically meaningful improvement in progression-free survival compared to standard-of-care chemoimmunotherapy in previously untreated adult patients with chronic lymphocytic leukemia.
